The week's 3 biggest stories
All 54 stories from the week are below, by topic.
- FDA approves durvalumab combination before and after surgery for bladder cancerFDA approval · The FDA approved the immunotherapy durvalumab with the antibody-drug conjugate enfortumab vedotin before surgery, followed by durvalumab, for adults with muscle-invasive bladder cancer who cannot or will not take cisplatin.
- FDA approves kinase inhibitor for tenosynovial giant cell tumorFDA approval · The FDA approved the kinase inhibitor pimicotinib for adults with symptomatic tenosynovial giant cell tumor when surgery could cause serious harm.
- Personalized therapy intismeran reduced recurrence in skin cancerPhase III trial · In a phase 3 trial, people with high-risk skin cancer removed by surgery received pembrolizumab with personalized therapy intismeran or placebo.
Clinical trials
- FDA approves kinase inhibitor for tenosynovial giant cell tumorStory 1
- Immunotherapy added to radiation did not help early-stage lung cancerStory 5
- The targeted drug risovalisib shrank ovarian cancer in a phase 2 trialStory 6
- Perioperative camrelizumab plus chemotherapy improved outcomes in head and neck cancerStory 21
- Immunotherapy plus chemotherapy improved event-free survival in pancreatic cancerStory 22
- Weekend breaks in dasatinib matched daily treatment for leukemiaStory 37
- A three-drug treatment showed activity in metastatic bowel cancerStory 41
Precision oncology
- The bispecific antibody anbenitamab improved control of breast cancerStory 3
- Guidelines recommend molecular testing for children with solid tumorsStory 7
- Targeted drug risovalisib shrank tumors in ovarian cancer trialStory 13
- Targeted drugs show activity against metastatic eye melanomaStory 20
- Targeted drugs show activity in metastatic eye melanomaStory 31
- Community programs helped address breast cancer screening gapsStory 38
- Gene patterns predicted treatment resistance in breast cancerStory 39
Antibody-drug conjugates
- TROP2 measure predicted outcomes with the antibody-drug conjugate datopotamab deruxtecan in lung cancerStory 4
- antibody-drug conjugate izalontamab brengitecan improves survival in advanced food pipe cancerStory 19
- Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 antibody-drug conjugate) in Advanced or Metastatic EGFR Mutated non-small cell lung cancerStory 29
- Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 antibody-drug conjugate) in Advanced or Metastatic EGFR Mutated non-small cell lung cancerStory 34
- FDA approves durvalumab combination before and after surgery for bladder cancerStory 36
- FDA approves durvalumab combination for muscle-invasive bladder cancerStory 46
- FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder CancerStory 49
Antibodies
- The HER2 antibody anbenitamab improved control of advanced breast cancerStory 12
- A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)Story 15
- FDA approves antibody treatment amivantamab for head and neck cancerStory 47
- FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCCStory 50
India access
- BDR Pharma to acquire controlling stake in Acme’s oral solid formulations business from PAGStory 17
- Policy shifts test pharma’s resilienceStory 18
- Compliance to National Cancer Grid of India Guidelines for Locally Advanced Cervical Cancer: Results From a Multicentric Observational Cohort in IndiaStory 35
- From volume to value: How India’s pharma industry can move up the global value chainStory 54
Cancer vaccines
Cancer-care delivery
Cell and gene therapy
Head and neck cancer
Cell therapy
Other
- Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformationStory 8
- Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer RiskStory 9
- Immune niche remodeling: sustaining CAR-T persistence in solid tumorsStory 10
- FDA Approves Pimicotinib for Symptomatic TGCTStory 14
- A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology ClinicsStory 16
- Perivascular epithelial remodeling is reflected in circulating cfDNA methylation signals as detection markers for early esophageal tumorigenesisStory 26
- Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment ErasStory 27
- Genomic Atlas Reveals Where Dog and Human Cancers DivergeStory 28
- Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence RiskStory 43
- Molecular Profiling for Precision Medicine in Adrenocortical Carcinoma: Real-World Data From the French Network ENDOCAN-COMETEStory 44
- When Safety Depends on Coincidence: A Near-Miss in Radium-223 Therapy Revealing Latent Vulnerabilities in Theranostics Emergency CareStory 45
- FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBCStory 51
- A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsStory 53